Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × L19-IL2 immunocytokine × Clear all

Phase

Phase 2 2 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Interventions

Cyclophosphamide 571 pembrolizumab 442 Paclitaxel 410 Gemcitabine 394 Cisplatin 389 Carboplatin 388 Radiotherapy 347 fludarabine 324 Nivolumab 305 Bevacizumab 252 Docetaxel 247 Irinotecan 232 Magnetic Resonance Spectroscopy 217 Fluorouracil 203 Dexamethasone 201 Capecitabine 197 Specimen Handling 196 Rituximab 188 Cytarabine 183 Oxaliplatin 182 Temozolomide 179 fludarabine phosphate 176 Biopsy 175 Ipilimumab 172 Etoposide 166 Lenalidomide 162 Leucovorin 155 Doxorubicin 155 Cetuximab 154 Bortezomib 152

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02086721 2017-05-31

L19-IL2

Maastricht Radiation Oncology

Phase 1 Completed

Other solid neoplasm

Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡